Live imaging in zebrafish reveals neu(trophil) insight into the metastatic niche

Journal of Pathology

Volumn 227, Issue 4, 2012, Pages 381-384

  Patton, E Elizabeth ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

micrometastasis; neutrophil; VEGFR; xenograft; zebrafish

Indexed keywords

BECLOMETASONE; VASCULOTROPIN INHIBITOR;

BONE MARROW CELL; CANCER CELL; CANCER INVASION; CELL INVASION; CELL MIGRATION; CELL TRANSPLANTATION; CLINICAL TRIAL (TOPIC); DISEASE COURSE; HEMATOPOIESIS; HOMEOSTASIS; IMAGING; IMMUNE SYSTEM; IN VIVO STUDY; LEUKOCYTE; MAMMAL; METASTASIS; MICROMETASTASIS; NEUTROPHIL; NONHUMAN; PRIMATE; PRIORITY JOURNAL; REVIEW; TUMOR VASCULARIZATION; ZEBRA FISH;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; NEOPLASM METASTASIS; NEUTROPHILS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS; ZEBRAFISH;

EID: 84863722194     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4051     Document Type: Review

References (36)

1. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
2. Nguyen DX,. Tracing the origins of metastasis. J Pathol 2011; 223: 195-204.
3. Nguyen DX, Bos PD, Massague J,. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009; 9: 274-284.
4. Egeblad M, Nakasone ES, Werb Z,. Tumors as organs: complex tissues that interface with the entire organism. Dev Cell 2010; 18: 884-901.
5. Psaila B, Lyden D,. The metastatic niche: adapting the foreign soil. Nat Rev Cancer 2009; 9: 285-293.
6. Peinado H, Lavotshkin S, Lyden D,. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol 2011; 21: 139-146.
7. Pittet MJ, Weissleder R,. Intravital imaging. Cell 2011; 147: 983-991.
8. Mione MC, Trede NS,. The zebrafish as a model for cancer. Dis Model Mech 2010; 3: 517-523.
9. Zhang L, Alt C, Li P, et al., An optical platform for cell tracking in adult zebrafish. Cytometry A 2012; 81: 176-182.
10. White RM, Sessa A, Burke C, et al., Transparent adult zebrafish as a tool for in vivo transplantation analysis. Cell Stem Cell 2008; 2: 183-189.
11. Amatruda JF, Patton EE,. Genetic models of cancer in zebrafish. Int Rev Cell Mol Biol 2008; 271: 1-34.
12. Zhao C, Wang X, Zhao Y, et al., A novel xenograft model in zebrafish for high-resolution investigating dynamics of neovascularization in tumors. PLoS One 2011; 6: e21768.
13. Nicoli S, Presta M,. The zebrafish/tumor xenograft angiogenesis assay. Nat Protoc 2007; 2: 2918-2923.
14. Tobia C, De Sena G, Presta M,. Zebrafish embryo, a tool to study tumor angiogenesis. Int J Dev Biol 2011; 55: 505-509.
15. Zon LI, Peterson RT,. In vivo drug discovery in the zebrafish. Nat Rev Drug Discov 2005; 4: 35-44.
16. Kaufman CK, White RM, Zon L,. Chemical genetic screening in the zebrafish embryo. Nat Protoc 2009; 4: 1422-1432.
17. Taylor KL, Grant NJ, Temperley ND, et al., Small molecule screening in zebrafish: an in vivo approach to identifying new chemical tools and drug leads. Cell Commun Signal 2010; 8: 11.
18. He S, Lamers GE, Beenakker JW, et al., Neutrophil-mediated experimental metastasis is enhanced by VEGFR inhibition in a zebrafish xenograft model. J Pathol 2012; DOI: 10.1002/path.4013.
19. Feng Y, Santoriello C, Mione M, et al., Live imaging of innate immune cell sensing of transformed cells in zebrafish larvae: parallels between tumor initiation and wound inflammation. PLoS Biol 2010; 8: e1000562.
20. Rouhi P, Jensen LD, Cao Z, et al., Hypoxia-induced metastasis model in embryonic zebrafish. Nat Protoc 2010; 5: 1911-1918.
21. Stoletov K, Kato H, Zardouzian E, et al., Visualizing extravasation dynamics of metastatic tumor cells. J Cell Sci 2010; 123: 2332-2341.
22. Renshaw SA, Trede NS,. A model 450 million years in the making: zebrafish and vertebrate immunity. Dis Model Mech 2012; 5: 38-47.
23. Ellis LM, Reardon DA,. Is there really a yin and yang to VEGF-targeted therapies? Lancet Oncol 2010; 11: 809-811.
24. Folkman J,. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6: 273-286.
25. Ellis LM, Reardon DA,. Cancer: the nuances of therapy. Nature 2009; 458: 290-292.
26. Vredenburgh JJ, Desjardins A, Herndon JE II, et al., Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25: 4722-4729.
27. de Groot JF, Fuller G, Kumar AJ, et al., Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro-oncology 2010; 12: 233-242.
28. Bergers G, Hanahan D,. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8: 592-603.
29. Paez-Ribes M, Allen E, Hudock J, et al., Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-231.
30. Loges S, Mazzone M, Hohensinner P, et al., Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 2009; 15: 167-170.
31. Cortez-Retamozo V, Etzrodt M, Newton A, et al., Origins of tumor-associated macrophages and neutrophils. Proc Natl Acad Sci USA 2012; 109: 2491-2496.
32. Ebos JM, Lee CR, Cruz-Munoz W, et al., Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15: 232-239.
33. Ebos JM, Lee CR, Christensen JG, et al., Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 2007; 104: 17069-17074.
34. Karaman MW, Herrgard S, Treiber DK, et al., A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26: 127-132.
35. North TE, Goessling W, Walkley CR, et al., Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature 2007; 447: 1007-1011.
36. Goessling W, Allen RS, Guan X, et al., Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models. Cell Stem Cell 2011; 8: 445-458.